Po­sei­da tees $150M IPO; Gilead sends HBV pro­gram back to Pre­ci­sion; New HIV da­ta from Mer­ck, Gilead

→ Join­ing the long list of biotechs to aim for a large pan­dem­ic IPO, Po­sei­da Ther­a­peu­tics set terms for a $150 mil­lion of­fer­ing, priced at $14-$16 per share. The No­var­tis-backed on­col­o­gy biotech had orig­i­nal­ly filed for a $115 mil­lion IPO last year but scrapped the plan, rais­ing $142 mil­lion in a Se­ries C. They filed again in June and list­ed the same goal be­fore ad­just­ing up­wards.

→ Two years af­ter an­nounc­ing an up-to $445 mil­lion col­lab­o­ra­tion. Pre­ci­sion Bio­sciences has re­gained rights to its he­pati­tis B pro­gram from Gilead. The deal, signed un­der the old John McHutchi­son regime at Gilead, was meant to use Pre­ci­sion’s nu­cle­as­es to clear HBV in vi­vo. Pre­ci­sion said it would look for new part­ners for their HBV pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.